Summary
Global Markets Direct’s, ‘Soligenix, Inc. - Product Pipeline Review - 2016’, provides an overview of the Soligenix, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Soligenix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Soligenix, Inc.
- The report provides overview of Soligenix, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Soligenix, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Soligenix, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Soligenix, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Soligenix, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soligenix, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Soligenix, Inc. Snapshot 5
Soligenix, Inc. Overview 5
Key Information 5
Key Facts 5
Soligenix, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Soligenix, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Soligenix, Inc. - Pipeline Products Glance 12
Soligenix, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Soligenix, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Soligenix, Inc. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Soligenix, Inc. - Drug Profiles 17
SGX-301 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
dusquetide 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SGX-203 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SGX-201 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RiVax 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SGX-202 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Ebola vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
human papillomavirus vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RiVax + SGX-204 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SGX-943 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Soligenix, Inc. - Pipeline Analysis 30
Soligenix, Inc. - Pipeline Products by Target 30
Soligenix, Inc. - Pipeline Products by Route of Administration 31
Soligenix, Inc. - Pipeline Products by Molecule Type 32
Soligenix, Inc. - Pipeline Products by Mechanism of Action 33
Soligenix, Inc. - Recent Pipeline Updates 34
Soligenix, Inc. - Dormant Projects 44
Soligenix, Inc. - Discontinued Pipeline Products 45
Discontinued Pipeline Product Profiles 45
BT-VACC 45
Soligenix, Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Soligenix, Inc., Key Information 5
Soligenix, Inc., Key Facts 5
Soligenix, Inc. - Pipeline by Indication, 2016 7
Soligenix, Inc. - Pipeline by Stage of Development, 2016 9
Soligenix, Inc. - Monotherapy Products in Pipeline, 2016 10
Soligenix, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
Soligenix, Inc. - Phase III, 2016 12
Soligenix, Inc. - Phase II, 2016 13
Soligenix, Inc. - Phase I, 2016 14
Soligenix, Inc. - IND/CTA Filed, 2016 15
Soligenix, Inc. - Preclinical, 2016 16
Soligenix, Inc. - Pipeline by Target, 2016 30
Soligenix, Inc. - Pipeline by Route of Administration, 2016 31
Soligenix, Inc. - Pipeline by Molecule Type, 2016 32
Soligenix, Inc. - Pipeline Products by Mechanism of Action, 2016 33
Soligenix, Inc. - Recent Pipeline Updates, 2016 34
Soligenix, Inc. - Dormant Developmental Projects,2016 44
Soligenix, Inc. - Discontinued Pipeline Products, 2016 45
Soligenix, Inc., Subsidiaries 46
List of Figures
Soligenix, Inc. - Pipeline by Top 10 Indication, 2016 7
Soligenix, Inc. - Pipeline by Stage of Development, 2016 9
Soligenix, Inc. - Monotherapy Products in Pipeline, 2016 10
Soligenix, Inc. - Pipeline by Target, 2016 30
Soligenix, Inc. - Pipeline by Route of Administration, 2016 31
Soligenix, Inc. - Pipeline by Molecule Type, 2016 32
Soligenix, Inc. - Pipeline Products by Mechanism of Action, 2016 33
